SCHEMBL6413206

SCHEMBL6413206

[CH2]c1cccc(OCC(C)C)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRIM24 O15164 1/20 0.46
TSHR P16473 1/20 0.45
MAPK1 P28482 1/20 0.45
NR1H4 Q96RI1 1/20 0.43
SIRT2 Q8IXJ6 1/20 0.43
LMNA P02545 1/20 0.41
HIF1A Q16665 1/20 0.41
KAT6A Q92794 1/20 0.41
FOS P01100 1/20 0.40
JUN P05412 1/20 0.40
MTNR1A P48039 3/20 0.40
MTNR1B P49286 3/20 0.40
ADRB2 P07550 1/20 0.40
ADRB1 P08588 1/20 0.40
PDK2 Q15119 1/20 0.39
POLB P06746 1/20 0.39
MAPT P10636 1/20 0.39
HPGD P15428 1/20 0.39
XBP1 P17861 1/20 0.39
HSD17B1 P14061 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2967940 0.86 TRIM24 (0.55) TRIM24TSHRMAPK1NR1H4SIRT2
SCHEMBL23523394 0.81 TSHR (0.41) TSHRMAPK1LMNAHIF1AMTNR1A
Ethylene SCHEMBL27542294 0.79 TP53 (0.52) TRIM24TSHRMAPK1NR1H4SIRT2
SCHEMBL7774111 0.79 MAPK1 (0.47) TSHRMAPK1HIF1AMTNR1AMTNR1B
SCHEMBL3723068 0.78 ADRB2 (0.59) TRIM24ADRB2ADRB1MAPT
SCHEMBL5786398 0.78 MAPK1 (0.64) TRIM24TSHRMAPK1LMNAMTNR1A
SCHEMBL6419825 0.78 FAAH (0.49) TRIM24TSHRMAPK1NR1H4SIRT2
SCHEMBL129082 0.78 TP53 (0.59) TSHRMAPK1LMNAMAPTHPGD
SCHEMBL3164505 0.77 CHRNB2 (0.54) TRIM24TSHRMAPK1NR1H4SIRT2
SCHEMBL255566 0.77 USP2 (0.49) TRIM24NR1H4KAT6AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103228643-B As the benzoxazole derivative of histamine h 4 receptor part BIOPROJET (FR) 2015-11-25 CN claimed
CN-103228643-A Benzazole derivatives as histamine H4 receptor ligands BIOPROJET SOC CIV 2013-07-31 CN claimed
US-11992012-B2 Diaminotriazine compounds BASF SE (DE) 2024-05-28 US disclosed
US-20210186021-A1 DIAMINOTRIAZINE COMPOUNDS BASF SE (DE) 2021-06-24 US disclosed
CN-103228643-B As the benzoxazole derivative of histamine h 4 receptor part BIOPROJET (FR) 2015-11-25 CN disclosed
EP-2900645-A1 3-PHENYLISOXAZOLIN DERIVATIVES WITH HERBICIDAL ACTION Bayer CropScience AG (DE) 2015-08-05 EP disclosed
CN-104582703-A H4 receptor inhibitors for treating tinnitus SENSORION 2015-04-29 CN disclosed
CN-103228643-A Benzazole derivatives as histamine H4 receptor ligands BIOPROJET SOC CIV 2013-07-31 CN disclosed
EP-1180765-B1 Optical recording medium and porphycene compound MITSUI CHEMICALS INC (JP) 2005-04-06 EP disclosed
EP-1180765-A1 Optical recording medium and porphycene compound Mitsui Chemicals, Inc. (JP) 2002-02-20 EP disclosed
US-6106999-A SENSITIVITY TO GENERAL-PURPOSE VISIBLE LIGHT LASER, SO THAT HIGH-SPEED SCANNING EXPOSURE IS POSSIBLE BY LASER, AND EXTREMELY FINE HIGH RESOLUTION CAN BE OBTAINED; CAN BE USED FOR COATING OR PRINTING UNDER SAFELIGHT IRRADIATING CONDITIONS MITSUI CHEMICALS (JP) 2000-08-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210186021-A1 DIAMINOTRIAZINE COMPOUNDS DDT, DAZAP1, DDC TRIM24 4711/4885TSHR 3261/4885MAPK1 3298/4885
US-11992012-B2 Diaminotriazine compounds DDT, DAZAP1, DDC TRIM24 4711/4885TSHR 3261/4885MAPK1 3298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.